Skip to main content

Table 3 On-animal flea counts in naturally infested homes when dogs were administered either fluralaner or afoxolaner oral treatments

From: Evaluation of fluralaner and afoxolaner treatments to control flea populations, reduce pruritus and minimize dermatologic lesions in naturally infested dogs in private residences in west central Florida USA

Treatment group # dogs at day 0   Days post-Treatmenta
    Day 0 Day 7 Day 14 Day 21 Day 28–30 Day 40–45 Day 54–60 Day 82–86
Fluralanerb 34 Geomeand 28.3 0.3 0.1 0.1 0.0 0.0 0.0 0.0
  range (5–155) (0–6) (0–3) (0–2) (0–0) (0–1) (0–0) (0–0)
  % controle   99.0 99.6 99.8 100.0 99.9 100.0 100.0
  % (#) dogs with no fleas 0.0
(0/34)
76.5
(26/34)
88.2
(30/34)
94.1
(32/34)
100.0
(34/34)
97.1
(33/34)
100.0
(33/33)
100.0
(33/33)
Afoxolanerc 27 Geomean 20.4 0.1 0.2 0.1 0.0 0.0 0.0 0.0
  range (5–178) (0–4) (0–2) (0–3) (0–1) (0–0) (0–1) (0–0)
  % control   99.3 99.2 99.6 99.9 100.0 99.9 100.0
  % (#) dogs with no fleas 0.0
(0/27)
85.2
(23/27)
81.5
(22/27)
92.6
(25/27)
96.3
(26/27)
100.0
(27/27)
96.2
(25/26)
100.0
(23/23)
  1. aIn both groups, dogs were treated on day 0. In the afoxolaner group, dogs were also treated once between days 28–30 and once between days 54–60
  2. bDogs were orally administered fluralaner chews (Bravecto® Merck Animal Health) according to label directions
  3. cDogs were orally administered afoxolaner chewables (NexGard® Merial, Inc.) according to label directions
  4. dGeometric mean numbers of fleas in visual area counts on pets
  5. e{(Day 0 geometric mean animal area flea counts—day x geometric mean animal area flea counts)/day 0 geometric mean animal area flea counts)} x 100